-

01:19:46 PM

LABP Stock News

LABP - Landos Biopharma Inc

09/19/23 8:00 AM

Nasdaq : LABP

conferencesclinical triallow float

Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress

RHEA-AI

positive

09/14/23 8:00 AM

Nasdaq : LABP

low float

Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells

Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with

RHEA-AI

neutral

08/09/23 8:00 AM

Nasdaq : LABP

earningslow float

Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results

Landos Biopharma, Inc. (NASDAQ: LABP), a

RHEA-AI

neutral

05/31/23 4:15 PM

Nasdaq : LABP

conferenceslow float

Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference

Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from

RHEA-AI

neutral

05/30/23 4:15 PM

Nasdaq : LABP

managementlow float

Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit

RHEA-AI

neutral

05/25/23 4:05 PM

Nasdaq : LABP

low float

Landos Biopharma Announces 1-for-10 Reverse Stock Split

Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock

RHEA-AI

neutral

05/12/23 8:00 AM

Nasdaq : LABP

earningslow float

Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical

RHEA-AI

neutral

03/23/23 8:00 AM

Nasdaq : LABP

low float

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

Landos Biopharma, Inc. (NASDAQ:

RHEA-AI

neutral

02/28/23 5:00 PM

Nasdaq : LABP

low float

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder

Landos Biopharma,

RHEA-AI

very positive

01/11/23 7:00 AM

Nasdaq : LABP

clinical triallow float

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization

Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for

RHEA-AI

very positive

LABP Data

IndustryPharmaceutical Preparation Manufacturing
Security nameLandos Biopharma Inc
SectorManufacturing

About Landos Biopharma Inc

there is an unmet need for new treatments for autoimmune diseases that transform paradigms and clinical practice. landos will address that unmet clinical need. we know physicians are tired of settling for mediocre therapies for patients living with autoimmune disorders. with one first in class, oral therapy for inflammatory bowel disease (ibd) and its two clinical manifestations: crohn’s disease and ulcerative colitis, showing remarkable preclinical results and entering clinical trials, our team is poised to soon offer ibd patients a better way. the bottom line is this: patients deserve treatment options that are safer, more effective, and less disruptive to their lives. that is what drives landos scientists and our team each and every day.